Background: Oligometastatic disease (OD) is usually defined arbitrarily as a condition in which there are ≤ 5 metastases. Given limited disease, it is expected that patients with OD should have better prognosis compared to other metastatic patients and that they can potentially benefit from metastasis-directed therapy (MDT). In this study, we attempted to redefine OD based upon objective evidence that fulfill these assumptions.

Methods: Chest CTSs of 773 patients with 15,947 lung metastases originating from ten malignancy types were evaluated. The number and largest diameter of each metastasis was recorded. Metastatic cluster was defined as a cluster of two or more metastases with diameter difference ≤ 1 mm. The prognostic power of seven statistical models on overall survival (OS) was analyzed.

Findings: Both the number of metastases and metastatic clusters had a highly significant impact on OS (p < 0.0001, p = 0.003 respectively). Patients with a single metastasis or a single cluster of metastases (regardless of metastases number), equaling 16.2% of all patients, had significantly better prognosis compared to other patients (p = 0.0002). If metastases diameter variability is ignored, as in the standard definition of OD, then patients with 2-5 and 6-10 metastases would have a similar prognosis.

Interpretation: Patients with a single cluster of metastases, theoretically originating from a single clone, have significantly better prognosis compared to patients with more than one cluster. Using this definition can potentially improve the results of MDT. The upper limit of metastases number should be determined by the technical capabilities of the MDT used.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902583PMC
http://dx.doi.org/10.1007/s12672-023-00625-2DOI Listing

Publication Analysis

Top Keywords

lung metastases
8
metastases
5
time redefining
4
redefining oligometastatic
4
oligometastatic disease?
4
disease? analysis
4
analysis lung
4
metastases ten
4
ten tumor
4
tumor types
4

Similar Publications

Background: Epidermal growth factor receptor (EGFR) gene mutations can lead to distant metastasis in non-small cell lung cancer (NSCLC). When the primary NSCLC lesions are removed or cannot be sampled, the EGFR status of the metastatic lesions are the potential alternative method to reflect EGFR mutations in the primary NSCLC lesions. This review aimed to evaluate the potential of magnetic resonance imaging (MRI) radiomics based on extrapulmonary metastases in predicting EGFR mutations through a systematic reviews and meta-analysis.

View Article and Find Full Text PDF

Lung cancer is the most common and deadly cancer worldwide. The 9th edition of the tumor node meta (TNM) classification system, effective from January 1, 2025, introduces significant updates. Notably, the N2 category is newly divided into N2a (single-station involvement) and N2b (multiple-station involvement), which reflects distinct prognostic implications.

View Article and Find Full Text PDF

Unusual Cause of Ventricular Arrhythmia.

JACC Case Rep

January 2025

Department of Cardiovascular Magnetic Resonance, Hôpital Privé Jacques Cartier, Institut Cardiovasculaire Paris Sud, Massy, France.

Although relatively rare, cardiac metastases represent a significant clinical challenge because of their impact on cardiac function and overall patient prognosis. This case presents a rare and atypical presentation of a patient with ventricular arrhythmia revealing a metastatic cancer in the heart. A 59-year-old man with lung cancer was admitted for chest tightness and episodes of syncope.

View Article and Find Full Text PDF

Acrometastasis is an extremely rare diagnosis, invariably associated with poor prognosis. A 60-year-old female with complaints of cough and breathing difficulty also presented with pain and swelling in her left leg. Radiological investigations suggested a double primary in the lung and leg; histopathology and immunohistochemistry (IHC) confirmed the lesion in the leg to be metastatic from the lung primary.

View Article and Find Full Text PDF

Microenvironmental Regulation of Dormancy in Breast Cancer Metastasis: "An Ally that Changes Allegiances".

Adv Exp Med Biol

January 2025

Laboratory of Tumor Heterogeneity, Metastasis and Resistance, Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland.

Breast cancer remission after treatment is sometimes long-lasting, but in about 30% of cases, there is a relapse after a so-called dormant state. Cellular cancer dormancy, the propensity of disseminated tumor cells (DTCs) to remain in a nonproliferative state for an extended period, presents an opportunity for therapeutic intervention that may prevent reawakening and the lethal consequences of metastatic outgrowth. Therefore, identification of dormant DTCs and detailed characterization of cancer cell-intrinsic and niche-specific [i.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!